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Supplementary Table 1. Data collection and refinement statistics for HHIP structures. 
 HHIP-N:SOS HHIP-N:apo HHIP-N:SOS  
(S-SAD) 
HHIP-C: heparin HHIP-C:SOS 
Data collection      
Space group P42212 P43212 P42212 C2 P3121 
Cell dimensions 
a, b, c (Å) 
α, β, γ (º) 
 
60.4, 60.4, 108.5 
90.0, 90.0, 90.0 
 
59.1, 59.1, 98.7 
90.0, 90.0, 90.0 
 
59.8, 59.8,108.7 
90.0, 90.0, 90.0 
 
170.6, 105.3, 148.4 
90.0, 96.0, 90.0 
 
100.6, 100.6, 311.9 
90.0, 90.0, 120.0 
No. crystals 1 1 8 1 1 
Wavelength (Å) 0.97620 0.96860 1.77120 0.97950 0.97949 









No. unique reflections 5609 (534) 5640 (420) 4801 (345) 71834 (3487) 72635 (3547) 
Completeness (%) 100.0 (100.0) 100.0 (100.0) 100.0 (100.0) 99.9 (98.4) 100.0 (99.9) 
Multiplicity 11.9 (10.9) 12.3 (12.3) 222.4 (20.9) 6.6 (5.8) 19.9 (20.0) 
⟨I/σ(I)⟩ 12.0 (1.1) 22.3 (1.4) 41.7 (2.0) 12.6 (0.8) 21.4 (0.8) 
Rmerge (%) 11.3 (182.7) 5.8 (180.7) 19.8 (137.3) 7.7 (221.8) 9.7 (431.9) 
Rpim (%) 3.5 (57.4) 2.4 (75.2) 1.2 (30.9) 3.3 (100.5) 2.2 (97.7) 
CC1/2 1.0 (0.4) 1.0 (0.5) 1.0 (0.8) 1.0 (0.3) 1.0 (0.3) 
      
Refinement      
Resolution 54.0-2.75 50.67-2.63 - 84.8–2.7 58.0-2.4 
No. reflections (test set) 5609 (288) 5602 (281) - 70890 (3635) 72499 (3664) 
Rwork / Rfree (%) 26.7 / 28.6 24.4 / 26.5 - 21.6 / 24.0 19.0 / 22.7 
No. atoms:      
Protein 964 807 - 10335 6843 
SOS 55 - - - 220 
Heparin - - - 140  
Water - - - - 37 
Ca2+ - - - - 2 
Glycerol - - -  6 
Average B factor (Å2):      
Protein 97.0 106.4 - 96.5 95.3 
SOS 195.2  - - 239.8 
Heparin   - 193.1 - 
Water   - - 70.8 
Ca2+   - - 136.6 
Glycerol   - - 108.8 
RMSD bond lengths 
(Å) 0.007 0.002 - 0.004 0.008 
RMSD bond angles (o) 0.9 0.5 - 0.9 1.0 
Ramachandran plot (%)      
Favoured 97.3 97.9 - 98.2 98.7 
Allowed 2.7 2.1 - 1.72 1.3 
Outliers 0 0 - 0.08 0 



































































































































































































































APDB accession codes are shown in parenthesis; BRoot-mean Square Deviation (RMSD) values were calculated 
for equivalent Cα atom positions using the program SHP 1,2; CNumber of equivalent Cα positions utilised in RMSD 
calculation via SHP; DSummed structural correlation (total probability) values calculated using SHP. The 
phylogenetic tree for analysed CRDs (Fig. 2a) was arranged using the program PHYLIP 3 with these summed 
structural correlation values to construct a distance matrix. Fz8-PAM – Frizzled 8-palmitoleate complex 4, Smo – 
Smoothened 5, Fz8 – Frizzled 8 6, sFRP3 – secreted Frizzled-related protein 6, MuSK – muscle-specific kinase 7, 
NPC1 – Niemann-Pick C1 protein 8, RFBP – riboflavin-binding protein 9, FRα – folate receptor α 10, FRβ – folate 






Supplementary Table 3. List of primers used in this study. 
Primer name Primer sequence Background 
HHIP-∆Hx_Fwd CGGCTAG ACCGGT 
TGCCTGAATGGGAAT
CCC 
Forward primer to clone HHIP-∆Hx 
HHIP-∆Hx_Rev CGGCTAG GGTACC 
GTCCACTTGTTCACA
TTG 






GCA GCA CAAGTC 
GCA 
GGACCAGCATCT 
Forward primer to introduce 
R185A/K186A/R189A mutations to 









Reverse primer to introduce 
R185A/K186A/R189Amutations to 








C GCA GCG CAC GCA 
CACAACTGC 
Forward primer to introduce 
K204A/R210A/K211A/K213A 











Forward primer to introduce 
K204A/R210A/K211A/K213A 
mutations to HHIP-∆Hx via overlap 
extension PCR 





Forward primer to generate N-HA-
tagged HHIP-∆Hx  





Forward primer to generate N-HA-
tagged HHIP-C 
 
N-HA-HHIP-∆Hx_Rev CGC GGTACC 
TCATTAGTCCACTTG
TTCACATTG 
Reverse primer to generate N-HA-









Forward primer to generate N-HA-
tagged HHIP-N 
 
N-HA-HHIP-N_Rev CGC GGTACC 
TCATTA 
GCTGATCTCTTCCAC 
Reverse primer to generate N-HA-
tagged HHIP-N (no C-tag) 
 




Forward primer to generate HHIP-C 
(used in conjunction with HHIP-
∆Hx_Rev) 
HHIP-C_K277N/G279T_Fwd CAAAGTGGAATA 
AAC GGA ACA 
GATGAAAGAGGACT
G 
Forward primer (1) to produce 
∆GAG site 1 mutant in HHIP-C via 









Reverse primer (1) to produce 
∆GAG site 1 mutant in HHIP-C via 
overlap extension PCR 
HHIP-C_R350N/H352_Fwd GCAGAACTCCAC 
AAT AAG ACT 
CTGGGAGGA 
 
Forward primer (2) to produce 
∆GAG site 1 mutant in HHIP-C via 






Reverse primer (2) to produce 
∆GAG site 1 mutant in HHIP-C via 







Forward primer (1) to produce 
∆GAG site 2 mutant in HHIP-C via 




Reverse primer (1) to produce 
∆GAG site 2 mutant in HHIP-C via 







Forward primer (2) to produce 
∆GAG site 2 mutant in HHIP-C via 




Reverse primer (2) to produce 
∆GAG site 2 mutant in HHIP-C via 




Forward primer used to combine 
∆GAG site 1 and ∆GAG site 2 
mutants into a single chain via 




Reverse primer used to combine 
∆GAG site 1 and ∆GAG site 2 
mutants into a single chain via 
overlap extension PCR 
CRISPR_guide_Fwd ACTGTCACAGACTGT
TACCG 
Forward primer for CRISPR 





Reverse primer for CRISPR EXTL3-
/- cell line generation 
CRISPR_seq_Fwd CGTCACAGAGGTCC
ACTTCC 
Forward primer for sequencing of 
EXTL3-/- cell line 
CRISPR_seq_Rev GAAAGCCAATGCTG
CTCCAC 
Reverse primer for sequencing of 









Supplementary Fig. 1. HHIP-N structure solution pipeline. (a-d) Models for the major steps of the structure 
solution process are displayed with the associated 2Fo-Fc electron density maps contoured at 1σ and displayed as 
a blue mesh. Two well-resolved features of HHIP-N, α1 of the CRD region (α-helix 1, left) and the SOS-binding 
helix (right), are displayed in boxes. (a) Output from the first Phenix Autosol/Autobuild cycle. (b) Second Phenix 
Autosol/Autobuild cycle. (c) Second refinement run from Refmac5 with the first appearance of electron density 
for a SOS molecule. (d) Final refinement step using AutoBUSTER. Both C and D were extended to 2.75 Å 
resolution and the final refined model is coloured orange versus yellow for partially-built models. (e) Anomalous 
difference map calculated from S-SAD data used for phasing is displayed as a yellow mesh contoured at 4σ and 







Supplementary Fig. 2. Structure-based sequence alignment of CRDs analysed in Figure 2. (a) Pocket-type 
CRDs. (b) Groove-type CRDs. HHIP-N helices are shown above the sequence using cylinders and dashed lines 
and are annotated as in Fig. 1c, with the 5 helices from the CRD region displayed in blue and the SOS-binding 
helix from the N-terminal GAG-binding domain in white. Loops 1 and 2 are outlined with yellow boxes, with 
DL1 and DL2 from HHIP-N highlighted in blue. Disulphide bonds present in HHIP-N are indicated using Roman 
numerals below sequence and indicated using orange boxes. The NPC1 β-sheet insert (see Fig. 2c) is highlighted 
in grey and indicated using a grey box. Residues 61-66 are absent in our HHIP-N structure and were not included. 







Supplementary Fig. 3. CRD structure comparison. (a) HHIP-N coloured as in Fig. 1b, with helices numbered 
α1-5 (coloured salmon) and DL1 and DL2 shown using green dashed lines. A potential central ligand-binding 
pocket is displayed using a dashed circle. (b-f) Related CRDs (labelled) in the same orientation as (a). Ligand-
binding loops are shown in green, and CRD helices superposed with those of HHIP-N are labelled and coloured 
salmon. Bound ligands (NPC1: cholesterol; SMO: cholesterol; RFBP: riboflavin; Fz8: palmitoleate) are displayed 







Supplementary Fig. 4. Detailed analysis of the HHIPN:PEG-cholesterol interaction measured by ITC. Raw 
isotherms obtained for HHIP-N:PEG-cholesterol (a, upper panel), buffer:PEG-cholesterol (b, upper panel) and 
HHIP-C:PEG-cholesterol (c, upper panel) with corresponding integrated heats of injection (lower panels). HHIP-
C was used as a control protein that did not show a specific interaction with PEG-cholesterol. d, Thermodynamic 
signature plots showing Gibbs free energy (∆G), enthalpy (∆H) and entropy (-T∆S) for the data shown in a-c with 
the addition of data from previously published PTCH:PEG-cholesterol data13. When the thermodynamic signature 
of each experiment is examined, the HHIP-N:PEG-cholesterol data reveal that the majority of the binding is due 
to a favourable enthalpic contribution, corresponding to a mainly hydrophobic interaction with a -T∆S of -22.2 
kJ/mol (contributing ~82% of the Gibbs free energy (∆G)) as is seen for other hydrophobic binding events (see 
for example14). In contrast, the thermodynamic signature of buffer:PEG-cholesterol shows an extremely 
unfavourable entropic interaction and huge errors for calculated enthalpies concomitant with high background of 
heat of dilution. As an additional control, PEG-cholesterol was titrated into HHIP-C, which has been shown to 
bind the globular part of SHH and not the lipid moieties15,16. A similar behaviour to that seen for buffer only was 
observed, with a poor fit and large errors: Kd = 37 µM ±55 µM, ∆H = -335 kJ/mol ±2600 and -T∆S = 310 kJ/mol. 
The striking difference between the buffer:PEG-cholesterol and HHIP-C:PEG-cholesterol interaction on one side, 
and the HHIP-N:PEG-cholesterol interaction on the other side is also well-represented by the thermodynamic 
signature plots for each of the experiments. Here, the HHIP-N:PEG-cholesterol interaction gives reasonable 
binding statistics with small errors. Importantly, this agrees with previously carried out ITC experiments of Hh 








Supplementary Fig. 5. Model of the full-length 1:1 HHIP-SHH complex in an extended (a) and closed (b) 
conformation. The length of the flexible linker between HHIP-N and HHIP-C (87.5 Å), and the SHH core domain 
and the cholesterol attachment were calculated estimated by multiplying the number of amino acids by ~3.4-4.0 
Å (see following link for details: https://bionumbers.hms.harvard.edu/bionumber.aspx?s=n&v=5&id=114332). 
The overlap between two circles/spheres suggests that the SHH-attached cholesterol moiety can potentially access 








Supplementary Fig. 6. HHIP-N crystal packing analysis. (a) Perpendicular view along the 4-fold 
crystallographic axis. Note that the asymmetric unit contains one HHIP-N and one SOS molecule. (b) 
Coordination of SOS molecules. Each HHIP-N molecule interacts with 3 SOS molecules, e.g. the HHIP-N chain 
displayed in blue and salmon binds SOS molecules 1, 2 and 3, whereas the grey HHIP-N molecule makes contacts 








Supplementary Fig. 7. Immunofluorescence microscopy in HEK293T cells of HA-tagged HHIP constructs 
bound to the cell surface. (a) N-HA-HHIP-N; (b) N-HA-HHIP-C; (c) N-HA-HHIP-ΔHx; (d) GPI-anchored N-
HA-RGMB 17 and (e) secreted GAG-binding Neurotrophin-3 (1D4-tagged) 18 Cells were transfected and fixed 
before staining with a primary mouse anti-HA antibody (Thermo Fisher) followed by a secondary Alexa Fluor® 
633-conjugated anti-Mouse IgG antibody (Thermo Fisher). Hoechst stain was added to stain cell nuclei 19. Anti-
HA antibody staining is displayed in magenta, nuclear staining in cyan. Images shown correspond to 








Supplementary Fig. 8. Structure solution of HHIP-C:GAG complexes. View of the 8-mer heparin molecule 
visible (red, a) and SOS molecules (pink, b), bound between HHIP-C chain A (EGF repeats; yellow) and a 
symmetry-related chain B (β-propeller; blue-green). Heparin residues are numbered using Roman numerals (odd, 
O2-Sulphoiduronic acid; even, N,O6-disulphoglucosamine) and the two SOS molecules are numbered as per 
Supplementary Fig. 7c (see below). The sigma-A weighted 2Fo-Fc (1.0 σ, blue) and Fo-Fc (green: +3.0 σ, red: -3.0 
σ) electron density maps are displayed. Residues observed to coordinate GAGs are highlighted (see 









Supplementary Fig. 9. HHIP-C:SOS complex crystal structure. (a) Arrangement of two HHIP-C chains (a 
and b; cartoon representation) around two centrally coordinated SOS molecules (stick representation). Colour 
coding is as for Fig.4. (b) Electrostatic surface potential shown from red (-8 kT/e) to blue (+8 kT/e) with SOS 
molecules displayed. (c) Close-up view of the boxed region from (a). SOS molecules are labelled SOS1 and SOS2 
and hydrogen bonds are displayed using dashed lines. Residues are coloured as in (a); two residues (R328, K329; 
grey) from a symmetry-related β-propeller region of HHIP-C chain B also contribute hydrogen-bonding 









Supplementary Fig. 10. Schematic of HHIP-C:GAG interactions. Residues contacting heparin (a) and SOS 
(b) are displayed. Atoms are coloured as follows: N, blue; O, red; S, yellow; C, black. Covalent bonds are coloured 
violet (GAG) and orange (HHIP-C), and brackets after amino acids correspond to the HHIP-C chains as designated 
in Fig. 3a and Supplementary Fig. 7. Hydrogen bonds are displayed as green dashed lines and labelled with lengths 
in Ångstrom. Red ‘eyelashes’ correspond to hydrophobic interactions. SGN, O2-Sulphoiduronic acid; IDS, N,O6-











Supplementary Fig. 11. Heparin affinity chromatography of HHIP-C constructs. (a) Rationale for the design 
of ∆GAG site mutants. N-linked sugar consensus sequences (N-X-T/S) were inserted into the two sites of GAG 
interaction (EGF repeats: pink; β-propeller: light blue). As shown in the zoomed-in panel, two N-glycans were 
inserted into each site (mutations: site 1 – K277N/G279N/R350N/H352T; site 2 – T603N/Y616T). The N-linked 
residue produced after mutation is displayed using colour-coded asterisks. (b) The elution of HHIP-C constructs 
was analysed using a heparin-binding assay. Elution was followed by absorption at 280 nm (colour-coded, inset) 
with the elution gradient displayed as a green trace. Wild-type HHIP-C (purple) binds with highest affinity, 
followed by the individual GAG site mutants (cyan and brown) and the dual GAG site mutant (grey). The HHIP-








Supplementary Fig. 12. Quantification of HH pathway inhibition in HS deficient mouse 3T3 fibroblasts in 
an Extl3-/- background. (a) Generation of mouse NIH/3T3 Extl3-/- cells. Gel showing successful gene editing, 
revealed by deletion of a segment of genomic DNA between the two guides, as shown in the schematic below. 
(b-d) Plots show the gating strategy used to identify cells that were transfected with two plasmids, each carrying 
one of the two guides used in the double-cut CRISPR strategy to ablate Extl3 (see methods). One plasmid encodes 
GFP and the second encodes mCherry so that doubly transfected cells will be positive for both GFP and RFP. 
Gating based on forward and back scatter (b) (FSC and BSC respectively) was used to indentify live cells (~73% 
of the population). Gating based on FSC width (W) vs height (H) (c) was used to identify single cells (~90% of 
the population of live cells). Finally, gating based on EGFP fluorescence (Y-axis) and mCherry fluorescence (X-
axis) (d) was used to find double transfected cells (0.71% of the single population from B in Quadrant 2 (Q2). 
Quadrants were set such that 0% of cells appeared in Q1, Q2, and Q4 in a mock-tranfected plate. All single cells 
isolated by this method were expanded and the knock-out of Extl3 confirmed by independent methods (see 
Supplementary Fig. 12e). (e) Cell surface HSPGs were measured in the indicated cell lines, including two clonal 
Extl3-/- cell lines, using staining with the anti-Heparan Sulfate HS20-1D4 antibody (see methods). Outliers 
eliminated using the ROUT method (Q=10%). (f) HH signalling assay to assess HHIP-C WT or HHIP-C Glu 
mutant inhibition of HH pathway activation in response to ShhN. Relative levels of Gli1 mRNA were quantified 
from 7 independent experiments, with statistical significance calculated using a two-tailed, paired t-test with 











Supplementary Fig. 13. HHIP-C dimer interactions. (a) Anti-parallel ‘head-to-tail’ dimer. The HHIP-
C:heparin complex crystal structure at 2.7 Å is displayed, with the protein backbone depicted in cartoon 
representation and the heparin molecule as sticks. A boxed region indicates the dimer interface (interface area = 
603 Å2; 5 hydrogen bonds, 55 van der Waals interactions); (b) ‘Head-to-head’ dimer. The asymmetric unit of the 
HHIP-C:SOS complex at 2.4 Å resolution (highest to date) is displayed, with the protein backbone depicted in 
cartoon representation and the SOS molecules as sticks. A boxed region indicates the dimer interface (dimer 










Supplementary Fig. 14. Analysis of the oligomeric behaviour of HHIP-N. (a) SEC-MALS analysis of HHIP-
N. Eluted peaks are shown as solid lines corresponding to refractive index readings (Y-axis 1), whilst the 
corresponding calculated molecular weights (MW) are shown as dotted lines for each peak (Y-axis 2). 
Concentrations are colour-coded (inset). (b-c) AUC experiments of HHIP-N (b) and HHIP-N: heparin (30-mer) 
complex (c). (d) Model for HHIP-N clustering. HHIP-N monomer:dimer equilibrium exists due to folding and 
unfolding of the N-terminal domain. GAGs are able to stabilise the N-terminal domain and therefore the dimer 
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